IN2014MN00144A - - Google Patents

Download PDF

Info

Publication number
IN2014MN00144A
IN2014MN00144A IN144MUN2014A IN2014MN00144A IN 2014MN00144 A IN2014MN00144 A IN 2014MN00144A IN 144MUN2014 A IN144MUN2014 A IN 144MUN2014A IN 2014MN00144 A IN2014MN00144 A IN 2014MN00144A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Andrew James Ledgard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IN2014MN00144A publication Critical patent/IN2014MN00144A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN144MUN2014 2011-07-08 2014-01-23 IN2014MN00144A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505685P 2011-07-08 2011-07-08
PCT/US2012/045254 WO2013009517A1 (en) 2011-07-08 2012-07-02 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

Publications (1)

Publication Number Publication Date
IN2014MN00144A true IN2014MN00144A (ko) 2015-06-19

Family

ID=46513872

Family Applications (1)

Application Number Title Priority Date Filing Date
IN144MUN2014 IN2014MN00144A (ko) 2011-07-08 2014-01-23

Country Status (22)

Country Link
US (1) US9481688B2 (ko)
EP (1) EP2729474B1 (ko)
JP (1) JP6050813B2 (ko)
KR (1) KR101582429B1 (ko)
CN (1) CN103703008B (ko)
AU (1) AU2012283035B2 (ko)
BR (1) BR112014000379A2 (ko)
CA (1) CA2840217C (ko)
DK (1) DK2729474T3 (ko)
EA (1) EA023460B1 (ko)
ES (1) ES2665035T3 (ko)
HR (1) HRP20180475T1 (ko)
HU (1) HUE037649T2 (ko)
IN (1) IN2014MN00144A (ko)
LT (1) LT2729474T (ko)
MX (1) MX341132B (ko)
NO (1) NO2729474T3 (ko)
PL (1) PL2729474T3 (ko)
PT (1) PT2729474T (ko)
RS (1) RS57207B1 (ko)
SI (1) SI2729474T1 (ko)
WO (1) WO2013009517A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015015491A8 (pt) * 2013-01-14 2018-01-23 Lilly Co Eli (tieno[2,3-b][1,5] benzoxazepin-4-il) piperazin-1-ila, seus usos, e composição farmacêutica.
TW201625644A (zh) 2014-04-29 2016-07-16 美國禮來大藥廠 作為選擇性5-HTA反向促效劑之(噻吩并[2,3-b][1,5]苯并氧氮呯-4-基)哌嗪-1-基化合物
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN108371660B (zh) * 2017-12-14 2020-03-10 五邑大学 一种四氢环戊二烯并吡咯化合物及其衍生物的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
US6828332B1 (en) * 1999-09-29 2004-12-07 Eli Lilly And Company Piperidine derivatives as reuptake inhibitors
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
US7807828B2 (en) * 2005-08-11 2010-10-05 Hypnion, Inc. Olanzapine analogs and methods of use thereof
BRPI0808828A8 (pt) * 2007-03-15 2017-11-28 Aryx Therapeutics Inc Compostos de dibenzo[b,f][1,4]oxazapina
CN105168219B (zh) * 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
GB0910009D0 (en) * 2009-06-10 2009-07-22 Glaxo Group Ltd Novel compounds
AR084867A1 (es) * 2011-02-07 2013-07-10 Lilly Co Eli Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual
BR112014004557A2 (pt) * 2011-08-30 2017-05-30 Lilly Co Eli compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ila como agonistas inversos de h1/antagonistas de 5-ht2a de dupla atividade

Also Published As

Publication number Publication date
CN103703008B (zh) 2015-11-25
HUE037649T2 (hu) 2018-09-28
PL2729474T3 (pl) 2018-08-31
US20140121199A1 (en) 2014-05-01
EP2729474A1 (en) 2014-05-14
HRP20180475T1 (hr) 2018-06-15
JP6050813B2 (ja) 2016-12-21
BR112014000379A2 (pt) 2017-01-10
KR101582429B1 (ko) 2016-01-04
CA2840217C (en) 2016-03-22
DK2729474T3 (en) 2018-05-22
MX2014000337A (es) 2014-11-13
CA2840217A1 (en) 2013-01-17
AU2012283035B2 (en) 2015-07-30
LT2729474T (lt) 2018-05-10
EA023460B1 (ru) 2016-06-30
KR20140029512A (ko) 2014-03-10
AU2012283035A1 (en) 2014-01-16
RS57207B1 (sr) 2018-07-31
US9481688B2 (en) 2016-11-01
CN103703008A (zh) 2014-04-02
ES2665035T3 (es) 2018-04-24
WO2013009517A1 (en) 2013-01-17
EA201391706A1 (ru) 2014-04-30
PT2729474T (pt) 2018-06-05
EP2729474B1 (en) 2018-03-14
SI2729474T1 (en) 2018-04-30
MX341132B (es) 2016-08-09
NO2729474T3 (ko) 2018-08-11
JP2014518280A (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
BR112013022641A2 (ko)
BR112013031251A2 (ko)
BR112013027245A2 (ko)
BR112013024383A2 (ko)
BR112013026905A2 (ko)
BR112013023185A2 (ko)
BR112013022995A2 (ko)
BR112013026744A2 (ko)
BR112013017670A2 (ko)
BR112013023927A2 (ko)
BR112013024365A2 (ko)
BR112013028733A2 (ko)
BR112013027121A2 (ko)
BR112013027452A2 (ko)
BR112013031556A2 (ko)
BR112013026790A2 (ko)
BR112013024588A2 (ko)
BR112013032368A2 (ko)
BR112013026895A2 (ko)
BR112013018949A2 (ko)
BR112013027761A2 (ko)
BR112013021637A2 (ko)
BR112013027836A2 (ko)
BR112013023266A2 (ko)
BR112013025487A2 (ko)